The increase in the number of people affected by COVID-19 (coronavirus) has generated great concern, and has forced a number of countries to implement measures in order to stop the spreading of the virus. These measures are, in many countries, very restrictive and can include social distancing and working from home in a situation of self-quarantine or isolation, in order to avoid infection of self, and others. Continue reading →

Whilst many people will only get mild to moderate symptoms of COVID-19 (coronavirus), myeloma and AL amyloidosis patients should be extra cautious during the current outbreak. The president of Myeloma Patients Europe (MPE), Hans Scheurer, sends a message to MPE members, myeloma and AL amyloidosis patients. Watch it below: Continue reading →

We are seeking a Patient Advocacy Programme Manager to join our growing team! Continue reading →

Myeloma Patients Europe (MPE), an European umbrella organisation representing myeloma and AL amyloidosis patient groups, is seeking an experienced Scientific Engagement Manager to develop the scientific and medical strategy of the organisation and to ensure all organisational programmes are underpinned by sound scientific information. Continue reading →

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for isatuximab (Sarclisa^®). The CHMP recommends this drug in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. Continue reading →

Collaboration between pharmaceutical companies and patient advocates often requires both parties to sign contracts covering various types of activities such as consultancy, collaborations, speaking engagements and advisory boards. These contracts define the terms and conditions of the engagements, covering such matters as confidentiality, intellectual property, copyright, data protection, compensation and other responsibilities of both parties. They typically also contain provisions, mandated by the pharmaceutical industry codes, designed to ensure an appropriate relationship between patient and pharmaceutical company. In the past, the complexity of these agreements has often been challenging for patient advocates to work with due to the contracts being long, difficult to understand and sometimes containing ambiguous clauses. Continue reading →

Myeloma Patients Europe (MPE) held a webinar on reimbursement and Health Technology Assessment (HTA) given by Neil Bertelsen, Steering Committee member at Health Technology Assessment International (HTAi). Continue reading →

Myeloma Patients Europe (MPE) will hold a webinar on big data in hematology on Thursday 2 April 2020 from 18:00 – 19:00 CET. Continue reading →

Myeloma Patients Europe (MPE) will hold a webinar on reimbursement and Health Technology Assessment (HTA) on Wednesday 18 March 2020 from 18:00 – 19:00 CET. Continue reading →